Fineline Cube

Follow:
14436 Articles
AstraZeneca's Imfinzi Approved for Limited Stage Small Cell Lung Cancer in China
CompanyDrug

AstraZeneca’s Imfinzi Approved for Limited Stage Small Cell Lung Cancer in China

Akeso Biopharma Wins NMPA Approval for New Cadonilimab Indication
CompanyDrug

Akeso Biopharma Wins NMPA Approval for New Cadonilimab Indication

Salubris Pharmaceuticals' Allisartan-Indapamide Hybrid Wins NMPA Approval
CompanyDrug

Salubris Pharmaceuticals’ Allisartan-Indapamide Hybrid Wins NMPA Approval

Wantai Biopharm's Cecolin 9 HPV Vaccine Approved by China's NMPA
CompanyDrug

Wantai Biopharm’s Cecolin 9 HPV Vaccine Approved by China’s NMPA

Biocytogen and Chia Tai Tianqing Win NMPA Approval for NTB003 Clinical Trials
CompanyDrug

Biocytogen and Chia Tai Tianqing Win NMPA Approval for NTB003 Clinical Trials

NMPA Accepts NDA for Innovent and HutchMed's Tyvyt and Elunate Combination
CompanyDrug

NMPA Accepts NDA for Innovent and HutchMed’s Tyvyt and Elunate Combination

SciBrunch Therapeutics Secures RMB 200 Million in Angel Financing Round
CompanyDeals

SciBrunch Therapeutics Secures RMB 200 Million in Angel Financing Round

JW Therapeutics' Carteyva Approved by Macau Health Bureau
CompanyDrug

JW Therapeutics’ Carteyva Approved by Macau Health Bureau

Sichuan Kelun-Biotech Raises $250M in Hong Kong's Largest Follow-On Offering
CompanyDeals

Sichuan Kelun-Biotech Raises $250M in Hong Kong’s Largest Follow-On Offering

Easton Pharma's Oxazepam Receives NMPA Approval and Partners with Nhwa
CompanyDeals

Easton Pharma’s Oxazepam Receives NMPA Approval and Partners with Nhwa

Sanofi's Rilzabrutinib Granted Orphan Drug Designation for Sickle Cell Disease
CompanyDrug

Sanofi’s Rilzabrutinib Granted Orphan Drug Designation for Sickle Cell Disease

Ascletis Pharma's Denifanstat Meets Phase III Endpoints in Severe Acne Trial
CompanyDrug

Ascletis Pharma’s Denifanstat Meets Phase III Endpoints in Severe Acne Trial